seed
Stage
1
Investors
About
Ligandal develops AI-driven peptide targeting and nanoparticle delivery technologies to precisely deliver therapeutic payloads, including gene editing tools, to specific cellular receptors for improved efficacy and reduced off-target effects.
Explore Ligandal's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.